Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 2/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 12/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SENP2 | Q9HC62 | 1/20 | 0.33 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25546325 | 0.89 | S1PR1 (0.50) | FBP1S1PR1S1PR3LMNAMAPT | |
| SCHEMBL25554218 | 0.87 | FBP1 (0.41) | FBP1S1PR1S1PR3LMNAMAPT | |
| SCHEMBL25546023 | 0.87 | FBP1 (0.41) | FBP1S1PR1S1PR3GRM2CSNK2A1 | |
| SCHEMBL25545941 | 0.81 | LMNA (0.48) | FBP1S1PR1LMNAMAPT | |
| SCHEMBL25545932 | 0.80 | FBP1 (0.44) | FBP1S1PR1LMNAMAPTGRM2 | |
| SCHEMBL25546361 | 0.79 | FBP1 (0.43) | FBP1LMNAMAPTNPSR1 | |
| SCHEMBL25546030 | 0.78 | FBP1 (0.42) | FBP1S1PR1LMNAMAPTGRM2 | |
| SCHEMBL25545928 | 0.78 | FBP1 (0.42) | FBP1S1PR1LMNAMAPTGRM2 | |
| SCHEMBL18282312 | 0.78 | FBP1 (0.48) | FBP1LMNAMAPT | |
| SCHEMBL25546328 | 0.77 | S1PR1 (0.43) | S1PR1S1PR3LMNAMAPTGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118103368-A | EIF4E inhibitors and uses thereof | 皮克医疗公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20230150997-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150997-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | FBP1 735/4885S1PR1 3861/4885S1PR3 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.